中国医药子公司天方药业富马酸伏诺拉生片获药品注册证书

Core Viewpoint - China National Pharmaceutical Group Co., Ltd. announced the approval of fumaric acid volnorelaxin tablets by the National Medical Products Administration, marking a significant step in the company's integrated layout of raw materials and formulations [1] Group 1: Product Approval and Specifications - The approved specifications for the drug are 10mg and 20mg, primarily used for treating reflux esophagitis and eradicating Helicobacter pylori in conjunction with antibiotics [1] - The total investment in the raw material and formulation project for this drug amounts to approximately 12.32 million RMB [1] Group 2: Market Potential and Sales Forecast - According to data from Minet, the estimated sales revenue for this drug in China's three major terminal markets is approximately 774 million RMB in 2024, with sales of about 778 million RMB in the first three quarters of 2025 [1] - Currently, a total of 40 production enterprises, including Tianfang Pharmaceutical, have obtained approval for this drug [1] Group 3: Strategic Implications - The approval is expected to enrich the company's product line and enhance its business layout [1] - Future sales performance may be influenced by uncertainties related to national policies and market conditions [1]